[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100516670":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":27,"centralContacts":32,"locations":38,"responsibleParty":57,"collaborators":60,"id":64,"slug":65,"hasResults":66,"nctId":67,"briefTitle":68,"officialTitle":68,"acronym":69,"eligibilityCriteria":70,"healthyVolunteers":71,"sex":72,"minAge":36,"maxAge":73,"enrollmentInfo":74,"targetDuration":36,"studyType":77,"phases":78,"briefSummary":80,"conditions":81,"keywords":84,"overallStatus":41,"whyStopped":36,"lastUpdateSubmitDate":88,"lastUpdatePostDateStruct":89,"startDateStruct":92,"completionDateStruct":94,"leadSponsor":96,"locationsCount":97},{"fullName":5,"class":6},"Endeavor Health","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Prophylactic Surfactant via Minimally Invasive Technique","EXPERIMENTAL","Infants randomized to prophylactic surfactant treatment will receive a dose of poractant alfa (Curosurf) administered under direct laryngoscopy using a surfactant instillation catheter (MIST) 16G Angiocath (Becton Dickinson, Sandy, UT, USA), at a dosage of 200 mg\u002Fkg as soon as possible after delivery (within 15 minutes).",[13],"Drug: Poractant Alfa",{"label":15,"type":16,"description":17,"interventionNames":18},"Rescue Surfactant via Minimally Invasive Technique","ACTIVE_COMPARATOR","The control group will be given surfactant will receive a dose of poractant alfa (Curosurf) administered under direct laryngoscopy using a surfactant instillation catheter (MIST) 16G Angiocath (Becton Dickinson, Sandy, UT, USA), at a dosage of 200 mg\u002Fkg if their fiO2 reaches a threshold of ≥30% within the first 48 hours of life.",[13],[20],{"type":21,"name":22,"description":23,"armGroupLabels":24,"otherNames":25},"DRUG","Poractant Alfa","Poractant alfa (Curosurf) 200mg\u002Fkg administered under direct laryngoscopy using a surfactant instillation catheter",[9,15],[26],"Minimally Invasive Surfactant Therapy",[28],{"name":29,"affiliation":30,"role":31},"Matthew Derrick, MBBS","Northshore Univ Healthsystem","PRINCIPAL_INVESTIGATOR",[33],{"name":29,"role":34,"phone":35,"phoneExt":36,"email":37},"CONTACT","8475702920",null,"mderrick@northshore.org",[39],{"facility":40,"status":41,"city":42,"state":43,"zip":44,"country":45,"countryCode":46,"cosmosGeoPoint":47,"geoPoint":52,"contacts":53},"Northshore University Healthsystem","RECRUITING","Evanston","Illinois","60201","United States","US",{"type":48,"coordinates":49},"Point",[50,51],-87.69006,42.04114,{"lat":51,"lon":50},[54],{"name":55,"role":34,"phone":56,"phoneExt":36,"email":37},"Matthew Derrick, mbbs","847-570-2920",{"type":31,"investigatorFullName":58,"investigatorTitle":59,"investigatorAffiliation":5,"oldNameTitle":36,"oldOrganization":36},"Matthew Derrick","Attending Neonatologist",[61],{"name":62,"class":63},"Chiesi USA, Inc.","INDUSTRY","100516670","phase-4-prophylactic-minimally-invasive-surfactant-evaluation-100516670",false,"NCT06007547","Prophylactic Minimally Invasive Surfactant Evaluation","PreProMISe","Inclusion Criteria:\n\n* Gestational age \\\u003C30 weeks\n* Antenatal consent from Parent\n\nExclusion Criteria:\n\n* Congenital anomalies\n* Alternate cause of respiratory distress",true,"ALL","15 Minutes",{"count":75,"type":76},200,"ESTIMATED","INTERVENTIONAL",[79],"PHASE4","The purpose of this study is to explore the question: Does prophylactic administration of exogenous surfactant in the delivery room, using a minimally-invasive technique, improve outcome in preterm infants 22-29 weeks' gestation compared to rescue treatment using the same technique?",[82,83],"Respiratory Distress Syndrome, Newborn","Premature Birth",[85,86,87],"Respiratory Distress Syndrome","surfactant","Minimally invasive Surfactant Therapy","2025-08-04",{"date":90,"type":91},"2025-08-07","ACTUAL",{"date":93,"type":91},"2024-01-01",{"date":95,"type":76},"2027-07-31",{"name":5,"class":6},1]